{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=54",
    "query": {
      "intervention": "Combination Group",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 2795,
    "total_pages": 280,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T02:52:26.500Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04839731",
      "title": "Combination 5-FU / Calcipotriene Cream for SCCIS/SCC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream",
          "type": "DRUG"
        },
        {
          "name": "Nourivan Base Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carilion Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-04-14",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04839731"
    },
    {
      "nct_id": "NCT02522572",
      "title": "Quantitating the Impact of Plerixafor",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transplants and Implants"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "plasmapheresis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "E. Steve Woodle",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2015-08",
      "completion_date": "2020-10",
      "has_results": false,
      "last_update_posted_date": "2020-06-30",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02522572"
    },
    {
      "nct_id": "NCT02786472",
      "title": "ConnectEd: A Randomized Controlled Trial Connecting Through Educational Training",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sexual Violence"
      ],
      "interventions": [
        {
          "name": "Online Bystander Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Online Substance Abuse Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "In-Person Bystander Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "In-Person Combination Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Heather Bush",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "17 Years to 24 Years"
      },
      "enrollment_count": 3178,
      "start_date": "2016-05",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786472"
    },
    {
      "nct_id": "NCT07843472",
      "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity or Overweight",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Petrelintide",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2026-09-30",
      "completion_date": "2030-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • Los Angeles, California • San Carlos, California + 3 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Carlos",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07843472"
    },
    {
      "nct_id": "NCT02542839",
      "title": "rTMS and Botulinum Toxin in Primary Cervical Dystonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Primary Cervical Dystonia",
        "Dystonia"
      ],
      "interventions": [
        {
          "name": "NeuroStar TMS therapy",
          "type": "DEVICE"
        },
        {
          "name": "Sham NeuroStar TMS therapy",
          "type": "DEVICE"
        },
        {
          "name": "Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)",
          "type": "OTHER"
        },
        {
          "name": "Craniocervical Dystonia Questionnaire (CDQ-24)",
          "type": "OTHER"
        },
        {
          "name": "Cerebellar-brain Inhibition (CBI)",
          "type": "OTHER"
        },
        {
          "name": "Botulinum toxin injections",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2015-11",
      "completion_date": "2021-06-28",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02542839"
    },
    {
      "nct_id": "NCT05827081",
      "title": "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Ansastrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1466,
      "start_date": "2024-02-28",
      "completion_date": "2030-09-20",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 79,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05827081"
    },
    {
      "nct_id": "NCT02740192",
      "title": "Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Adductor Canal Block",
          "type": "PROCEDURE"
        },
        {
          "name": "Periarticular Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2016-04",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740192"
    },
    {
      "nct_id": "NCT04023019",
      "title": "Treatment of Hemophilia A Patients With FVIII Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Octanate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wilate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emicizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant factor VIIa (rFVIIa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated prothrombin complex concentrate (aPCC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-03-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04023019"
    },
    {
      "nct_id": "NCT07157865",
      "title": "Comparing Prism Adaptation Training With and Without TENS to Minimize Unilateral Spatial Neglect",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Unilateral Spatial Neglect",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Prism adaptation training combined with TENS",
          "type": "DEVICE"
        },
        {
          "name": "PAT only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Kettering Health Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-09-30",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 1,
      "location_summary": "Centerville, Ohio",
      "locations": [
        {
          "city": "Centerville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07157865"
    },
    {
      "nct_id": "NCT02908165",
      "title": "Randomized Phase II Trial of Chemoembolization and Sorafenib",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "conventional TACE in combination with sorafenib, administered on a continuous schedule",
          "type": "DRUG"
        },
        {
          "name": "conventional TACE in combination with sorafenib, administered on a sequential schedule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-06",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2018-01-10",
      "last_synced_at": "2026-11-17T02:52:26.500Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02908165"
    }
  ]
}